Korean Post-marketing Surveillance for Orencia

Trial Profile

Korean Post-marketing Surveillance for Orencia

Phase of Trial: Phase IV

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Abatacept (Primary)
  • Indications Juvenile rheumatoid arthritis; Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 08 Nov 2017 Results (n=341) assessing DAS28P as a predictor of EULAR response to abatacept in patients with RA, were presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
    • 08 Mar 2016 Status changed from recruiting to completed as per ClinicalTrials.gov record.
    • 04 Aug 2014 Planned End Date changed from 1 Mar 2016 to 1 Jul 2016 according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top